<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947683</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 1918</org_study_id>
    <nct_id>NCT04947683</nct_id>
  </id_info>
  <brief_title>Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil</brief_title>
  <acronym>ALK</acronym>
  <official_title>Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, retrospective cohort study that will include patients diagnosed with NSCLC and&#xD;
      ALK rearrangement between January 2015 and December 2020.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>- Describe the treatment sequencing of ALK positive advanced NSCLC in a real-world setting.</measure>
    <time_frame>December of 2020</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- Describe the timelines from the appearance of symptoms, histopathological diagnosis, application of the molecular test, and start of treatment.</measure>
    <time_frame>December of 2020</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Estimate the progression-free survival of first-line treatment, and other subsequent lines;</measure>
    <time_frame>December of 2020</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>- Estimate the overall survival from diagnosis</measure>
    <time_frame>December of 2020</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>- Compare patients' outcomes among baseline characteristics defined subgroups;</measure>
    <time_frame>December of 2020</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>- Evaluate health economics parameters in the context.</measure>
    <time_frame>December of 2020</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnostic patients with NSCLC and ALK rearrangement between January 2015 and December&#xD;
        2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years;&#xD;
&#xD;
          -  Newly diagnosed advanced stage IIIB-IV NSCLC (AJCC 8th edition) or locally&#xD;
             advance/distant relapse in the period of January 2015 to December 2020.&#xD;
&#xD;
          -  NSCLC with pathological confirmation of ALK rearrangement by immunohistochemistry,&#xD;
             fluorescent in situ hybridization (FISH) or next generation sequencing (NGS);&#xD;
&#xD;
          -  ECOG 0-4;&#xD;
&#xD;
          -  Patients with CNS metastases are also considered eligible, regardless of the initial&#xD;
             treatment instituted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Incomplete medical chart in terms of date of diagnosis, ALK test results and outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eldsamira Mascarenhas, MD</last_name>
    <phone>+55 71 3496 3744</phone>
    <email>samira@nob-ba.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Gelatti, MD</last_name>
    <phone>+55 51. 3320.3236</phone>
    <email>anagelatti@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Regional Integrado de Oncologia (CRIO)</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Henrique Cronenberger, MD</last_name>
      <phone>+55 85 32865934</phone>
      <email>eduardenrique@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liga Norte Riograndense Contra o Câncer</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59075-740</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielli Matias, MD</last_name>
      <phone>55 84 4009 5595</phone>
      <email>danielli.matias@liga.org.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto D'OR</name>
      <address>
        <city>Rio De Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarissa Baldotto, MD</last_name>
      <phone>55 21 32076585</phone>
      <email>cbaldotto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Clarissa Baldotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CPO Pucrs</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Gelatti, MD</last_name>
      <phone>+55 51. 3320.3236</phone>
      <email>anagelatti@yahoo.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.C Camargo Cancer Center</name>
      <address>
        <city>São Paulo</city>
        <zip>01525-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Corassa, MD</last_name>
      <phone>+5511985883170</phone>
      <email>marcelo.corassa@accamargo.org.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Non-Small-Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

